Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …

Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

Abstract Background and Aims: The GEMINI long-term safety [LTS] study is a continuing
phase 3 trial investigating the safety and efficacy of vedolizumab, an α4β7 integrin …

Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, are an
important cause of morbidity and impact significantly on quality of life. Overall, current …

Background Biological tumor necrosis factor (TNF) inhibitors have revolutionized the
treatment of inflammatory bowel disease and redefined treatment goals to include mucosal …

Nocebo effects encompass negative responses to inert interventions in the research setting
and negative outcomes with active treatments in the clinical research or practice settings …

Antibiotic abuse can lead to gut microbiota disturbance and intestinal inflammation, which in
turn may lead to serious inflammatory bowel disease and metabolic syndromes. To …

Inflammatory bowel diseases (IBD) such as Crohn's Disease (CD) and Ulcerative Colitis
(UC) are chronic, progressive, and relapsing disorders of the gastrointestinal tract (GIT) …

Inflammatory bowel disease (IBD) is a chronic condition that significantly affects the quality
of life of its patients. Biologic drugs have been the mainstay treatment in the management of …

Well-designed randomized controlled trials (RCTs) provide the best evidence of the primary
research designs for evaluating the effectiveness of interventions. However, if RCTs are …